Merck & Co., Inc. (NYSE:MRK) Shares Bought by Rock Creek Group LP

Rock Creek Group LP increased its holdings in Merck & Co., Inc. (NYSE:MRK) by 20.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,661 shares of the company’s stock after purchasing an additional 942 shares during the quarter. Rock Creek Group LP’s holdings in Merck & Co., Inc. were worth $440,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in MRK. Biltmore Family Office LLC increased its position in shares of Merck & Co., Inc. by 0.3% during the 1st quarter. Biltmore Family Office LLC now owns 44,156 shares of the company’s stock worth $3,433,000 after purchasing an additional 132 shares in the last quarter. Resources Management Corp CT ADV grew its stake in Merck & Co., Inc. by 0.7% during the first quarter. Resources Management Corp CT ADV now owns 17,775 shares of the company’s stock worth $1,370,000 after buying an additional 132 shares during the last quarter. Rice Partnership LLC increased its holdings in shares of Merck & Co., Inc. by 3.6% during the second quarter. Rice Partnership LLC now owns 3,826 shares of the company’s stock worth $298,000 after buying an additional 133 shares in the last quarter. Well Done LLC raised its stake in shares of Merck & Co., Inc. by 4.0% in the second quarter. Well Done LLC now owns 3,508 shares of the company’s stock valued at $273,000 after acquiring an additional 134 shares during the last quarter. Finally, Bar Harbor Trust Services grew its position in Merck & Co., Inc. by 1.0% during the 1st quarter. Bar Harbor Trust Services now owns 13,583 shares of the company’s stock worth $1,047,000 after acquiring an additional 136 shares during the last quarter. 71.83% of the stock is owned by institutional investors and hedge funds.

Shares of Merck & Co., Inc. stock opened at $72.11 on Wednesday. The firm has a fifty day moving average of $76.68 and a two-hundred day moving average of $76.59. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.06 and a current ratio of 1.31. The stock has a market capitalization of $182.54 billion, a price-to-earnings ratio of 32.93, a PEG ratio of 2.16 and a beta of 0.41. Merck & Co., Inc. has a 52 week low of $71.71 and a 52 week high of $86.30.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Wednesday, July 28th. The company reported $1.31 EPS for the quarter, meeting analysts’ consensus estimates of $1.31. Merck & Co., Inc. had a return on equity of 50.93% and a net margin of 11.48%. The business had revenue of $11.40 billion during the quarter, compared to the consensus estimate of $11.21 billion. During the same quarter in the prior year, the company posted $1.37 earnings per share. As a group, research analysts forecast that Merck & Co., Inc. will post 5.51 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 7th. Investors of record on Wednesday, September 15th will be paid a dividend of $0.65 per share. This represents a $2.60 annualized dividend and a yield of 3.61%. The ex-dividend date is Tuesday, September 14th. Merck & Co., Inc.’s payout ratio is 43.77%.

MRK has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. reduced their price objective on Merck & Co., Inc. from $105.00 to $100.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 9th. Truist began coverage on shares of Merck & Co., Inc. in a report on Tuesday, July 27th. They set a “buy” rating and a $92.00 price objective on the stock. Truist Securities started coverage on shares of Merck & Co., Inc. in a research note on Tuesday, July 27th. They issued a “buy” rating and a $76.79 target price for the company. Morgan Stanley cut shares of Merck & Co., Inc. from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $90.00 to $85.00 in a research note on Tuesday, September 7th. Finally, SVB Leerink boosted their price objective on shares of Merck & Co., Inc. from $99.00 to $101.00 and gave the stock an “outperform” rating in a research report on Friday, July 30th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Merck & Co., Inc. has an average rating of “Buy” and a consensus target price of $91.09.

Merck & Co., Inc. Profile

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

See Also: How To Calculate Debt-to-Equity Ratio

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.